RMD Open

Birth length and perinatal exposures and rheumatoid arthritis risk in the E3N cohort

Objective To examine associations between participants’ perinatal factors, including harmonised birth weight and length, ...
RMD Open

Emotional well-being at diagnosis may indicate future mental health risk in patients with juvenile idiopathic arthritis: data from the German inception cohort ICON

Objectives To determine the prevalence of depressive and anxiety symptoms among young people 7 years and 9 years after ...
RMD Open

Severe thrombocytopenia in antiphospholipid syndrome: a retrospective study of 432 patients

Introduction Antiphospholipid syndrome (APS) is an autoimmune disease characterised by obstetric morbidity and recurrent ...
rmdopen.bmj

Systemic lupus erythematosus damage risk index (SLE-DRI): a simple machine learning-based tool for identifying patients at risk for early organ damage

Objective Organ damage is a key determinant of poor prognosis and increased mortality in systemic lupus erythematosus (SLE). However, no validated clinical tools for predicting damage accumulation ...
rmdopen.bmj

Hydroxychloroquine and pregnancy outcomes in patients with anti-phospholipid syndrome: a systematic review and meta-analysis

Background About 20% of female patients with anti-phospholipid syndrome (APS) experience obstetric complications despite standard treatment with aspirin and heparin. Treatment with hydroxychloroquine ...
rmdopen.bmj

Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies

Objective To assess the efficacy of long-term treatment with risankizumab across the updated Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains and key related ...
rmdopen.bmj

Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term ...

Objectives This 1-year long-term extension (LTE) study (NCT04451772) followed the 48-week phase 2 SLEek study (NCT03978520) that evaluated upadacitinib (a Janus kinase inhibitor) alone or combined ...
rmdopen.bmj

Persistent-relapsing SARS-CoV-2 infection following rituximab treatment for autoimmune rheumatic diseases: diagnosis and outcomes

Background COVID-19 may persist or relapse in patients on B-cell depleting biologic therapies. Objective To examine the rate and outcome of persistent-relapsing COVID-19 (prCOVID-19) in patients with ...
rmdopen.bmj

Patients with psoriatic arthritis and comorbid metabolic syndrome show a difficult-to-treat phenotype: another mosaic tile in the definition of a still undefined subset of patients

Objective Psoriatic arthritis (PsA) is a chronic inflammatory condition associated with psoriasis and characterised by heterogeneous clinical manifestations, including peripheral and axial arthritis, ...
rmdopen.bmj

Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease

Objectives Evaluate the risks and benefits of upadacitinib 15 mg vs adalimumab in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate based on cardiovascular (CV) risk.
rmdopen.bmj

DEUS Enthesitis Index (DEI): a new tool integrating ultrasound and clinical examination for enthesitis assessment in spondyloarthritis

Objectives (1) To develop a composite score, the DEUS (Defining Enthesitis on Ultrasound in Spondyloarthritis) Enthesitis Index (DEI), which integrates ultrasound and clinical examination findings for ...
rmdopen.bmj

Lung ultrasound outperforms symptom-based screening to detect interstitial lung disease associated with rheumatoid arthritis

Objectives Interstitial lung disease associated with rheumatoid arthritis (RA-ILD) is linked to high mortality. Currently, effective screening tools are lacking. We assessed the role of symptoms and ...